Atossa Therapeutics (ATOS) announced that five abstracts featuring data on (Z)-endoxifen have been accepted for presentation at the San Antonio Breast Cancer Symposium, SABCS, taking place December 10-13, 2024, in San Antonio, Texas. The presentations will showcase significant findings from various studies evaluating the use of (Z)-endoxifen in breast cancer prevention and treatment, including phase 2 trials and innovative combination therapy research. “We are excited to present a comprehensive body of research on (Z)-endoxifen at SABCS 2024,” said Dr. Steven Quay, President and Chief Executive Officer of Atossa Therapeutics. “These presentations highlight our commitment to advancing breast cancer treatment and prevention, showcasing the potential of (Z)-endoxifen to bring meaningful treatment options to patients with breast cancer.”
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics: Q3 2024 Financial Results and Updates
- Atossa Therapeutics reports Q3 EPS (6c), consensus (6c)
- Atossa Therapeutics, Inc. (ATOS) Q3 Earnings Cheat Sheet
- Atossa Therapeutics appoints Claudia Lopez as VP, clinical development
- Atossa repots topline data from the KARISMA-Endoxifen Phase 2 study